Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs
29 November 2023 - 6:59AM
Dow Jones News
By Josh Beckerman
Cabaletta Bio shares were down 32% to $12.72 after the U.S. Food
and Drug Administration said it is looking into reports of T-cell
malignancies in patients who received treatment with BCMA- or
CD19-directed autologous CAR T cell immunotherapies.
Cantor Fitzgerald analyst Josh Schimmer also mentioned Gracell
Biotechnologies and Autolus Therapeutics as stocks that were
"obviously" down in connection with the FDA's announcement. Gracell
was recently down 17% to $4.46 while Autolus declined 11% to $4.50.
Schimmer said the FDA investigation is "Likely a Storm in A Tea
Cup."
The FDA lists several approved products in the category, such as
Yescarta from Gilead Sciences. It said "the overall benefits of
these products continue to outweigh their potential risks for their
approved uses."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 28, 2023 14:44 ET (19:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2024 to May 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From May 2023 to May 2024
